BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31263838)

  • 1. Clinical relevance and accuracy of p63 and TTF-1 for better approach of small cell lung carcinoma versus poorly differentiated nonkeratinizing squamous cell carcinoma.
    Gurguş D; Grigoraş ML; Motoc AGM; Zamfir CL; Cornianu M; Faur CI; Pop DL; Folescu R
    Rom J Morphol Embryol; 2019; 60(1):139-143. PubMed ID: 31263838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.
    Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE
    Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material.
    Kalhor N; Zander DS; Liu J
    Mod Pathol; 2006 Aug; 19(8):1117-23. PubMed ID: 16680154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.
    Wu M; Szporn AH; Zhang D; Wasserman P; Gan L; Miller L; Burstein DE
    Diagn Cytopathol; 2005 Oct; 33(4):223-7. PubMed ID: 16138374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas.
    Sinna EA; Ezzat N; Sherif GM
    J Egypt Natl Canc Inst; 2013 Dec; 25(4):209-18. PubMed ID: 24207093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas.
    Kargi A; Gurel D; Tuna B
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):415-20. PubMed ID: 18091384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of TTF-1, NapsinA, P63, CK5/6 in Lung Cancer and Its Diagnostic Values for Histological Classification].
    Yu H; Li L; Liu D; Li WM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):336-341. PubMed ID: 28616902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
    Argon A; Nart D; Veral A
    Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual color multiplex TTF-1 + Napsin A and p63 + CK5 immunostaining for subcategorizing of poorly differentiated pulmonary non-small carcinomas into adenocarcinoma and squamous cell carcinoma in fine needle aspiration specimens.
    Sethi S; Geng L; Shidham VB; Archuletta P; Bandyophadhyay S; Feng J; Madan S; Shi D; Tranchida P; Giorgadze T
    Cytojournal; 2012; 9():10. PubMed ID: 22582081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach.
    Zhang H; Liu J; Cagle PT; Allen TC; Laga AC; Zander DS
    Mod Pathol; 2005 Jan; 18(1):111-8. PubMed ID: 15309021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of ΔNp63 expression in lung non-small cell carcinomas.
    Nonaka D
    Am J Surg Pathol; 2012 Jun; 36(6):895-9. PubMed ID: 22367298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
    Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H
    J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
    van Zyl A; Schubert PT; Koegelenberg CFN
    Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
    Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
    Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p63 immunostaining in destained bronchoscopic cytological specimens.
    Shtilbans V; Szporn AH; Wu M; Burstein DE
    Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1.
    Xu XY; Yang GY; Yang JH; Li J
    Pathol Res Pract; 2014 Oct; 210(10):680-5. PubMed ID: 25063315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.
    Wang BY; Gil J; Kaufman D; Gan L; Kohtz DS; Burstein DE
    Hum Pathol; 2002 Sep; 33(9):921-6. PubMed ID: 12378518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
    Kim MJ; Shin HC; Shin KC; Ro JY
    Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung.
    Whithaus K; Fukuoka J; Prihoda TJ; Jagirdar J
    Arch Pathol Lab Med; 2012 Feb; 136(2):155-62. PubMed ID: 22288962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
    Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S
    Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.